<DOC>
	<DOCNO>NCT00134368</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety etanercept adult vitiligo .</brief_summary>
	<brief_title>Study Efficacy Safety Etanercept Adults With Vitiligo</brief_title>
	<detailed_description>Subjects self-administer etanercept 50 mg SQ twice weekly 6 month . Lesion repigmentation evaluate monthly visit .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Vitiligo patient age 18 year old Vitiligo patient evaluable lesion ; duration 3 month 10 year . Disease interfere significantly quality life and/or involve 3 % body surface area Subjects must negative tuberculin ( TB ) skin test entry study If subject female childbearing potential , must agree use adequate contraception ( adequate contraception include abstinence ) must negative serum pregnancy test day administration study medication . If subject male reach puberty , must agree use adequate contraception study 1 month discontinuation study . Subject designee must ability selfinject investigational product care giver home administer subcutaneous injection Subject must able give informed consent ; must authorize release use protect health information ; , applicable , must assent participate prior enrollment study . Unable consent History noncompliance therapy Concurrent therapy vitiligo Systemic phototherapy within 4 week Topical therapy within 2 week Any medical condition etanercept would contraindicate Any internal malignancy within 5 year ( fully excise cutaneous , basal cell carcinoma squamous cell carcinoma exception ) Pregnancy , practice effective birth control , inability practice safe sex length study . Lactation History alcohol drug abuse one year study . Any participation another investigational drug study 4 week precede study . Known HIVpositive status ; know history mycobacterial disease immunosuppressing disease . Presence grade 3 4 infection &lt; 30 day prior screen visit ; screen visit first day treatment study ; time study , opinion Investigator , would preclude participation study . Patients receive live vaccine 3 month prior , , study . A prior history tuberculosis , and/or positive PPD skin test positive CXR screening . Patients previous current exposure follow TNF antagonist : etanercept ( Enbrel ) ; adalimumab ( Humira ) ; infliximab ( Remicade ) . These patient eligible , even washout . Patients previous current exposure Kineret NOT eligible , even washout . However , patient prior current exposure biologics direct Tcells ( e.g . alefacept , efalizumab , siplizumab , etc . ) eligible enrollment study washout period 4 week first dose study drug ( baseline visit ) . It protocol specific also . The subject , Investigator 's opinion , chronic , severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiovascular ( congestive heart failure [ CHF ] severity ; myocardial infarction [ MI ] , cerebrovascular accident [ CVA ] transient ischemic attack [ TIA ] within 3 month screen visit ; unstable angina pectoris ; uncontrolled hypertension [ sit systolic blood pressure ( BP ) &lt; 80 mm Hg &gt; 160 diastolic BP &gt; 100 mm Hg ] ) , neurological disease ; know systemic lupus erythematosus ( SLE ) ; diabetes ; concomitant medical condition place participant risk participate study and/or may interfere conduct study . Chronic hepatitis B hepatitis C , SLE , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>vitiligo</keyword>
	<keyword>etanercept</keyword>
</DOC>